1-8 of 8
Shachar Peles
Close
Sort by
Journal Articles

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, John M. Burke, Bertrand Anz, Shachar Peles, Jeff P. Sharman, Praveen K. Tumula, Juliana M. L. Biondo, Prachi Jani, Mei Wu, Tony Lin, Neha Parmar, Yong Mun, Nai-Shun Yao, Steven Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3029.
https://doi.org/10.1182/blood-2023-177917
Published: 2023
Journal Articles

Outcomes of Thromboembolism in COVID-19 Cancer Patients Vs Non-Cancer Patients

Can Jones, Kristina Menchaca, Catherine Ostos, Jeffery Durbin, Kai Chen, Shachar Peles
Journal: Blood
Blood (2022) 140 (Supplement 1): 5660.
https://doi.org/10.1182/blood-2022-157218
Published: 2022
Journal Articles

Ibrutinib Therapy in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Analysis By Prior Rituximab Treatment and Baseline Mutations

Robert Chen, MD, Sven de Vos, MD PhD, Catherine Thieblemont, MD PhD, Peter Martin, FRCPC, MD MS, Christopher Flowers, MD, Franck Morschhauser, MD PhD, Graham Collins, MD PhD, Shuo Ma, MD, Morton Coleman, MD, Shachar Peles, MD, Stephen D. Smith, MD, Jacqueline C. Barrientos, MD, Alina Smith, Brian Munneke, PhD, Shiquan Wu, PhD, Leo Cheung, PhD, Kevin Kwei, PhD, Selda Samakoglu, MD PhD, Israel Arango-Hisijara, MD, Isaiah Dimery, MD, Ariela Noy, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3026.
https://doi.org/10.1182/blood.V130.Suppl_1.3026.3026
Published: 2017
Journal Articles

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Clinical Trials & Observations
Ariela Noy, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher R. Flowers, Franck Morschhauser, Graham P. Collins, Shuo Ma, Morton Coleman, Shachar Peles, Stephen Smith, Jacqueline C. Barrientos, Alina Smith, Brian Munneke, Isaiah Dimery, Darrin M. Beaupre, Robert Chen
Journal: Blood
Blood (2017) 129 (16): 2224–2232.
https://doi.org/10.1182/blood-2016-10-747345
Published: 2017
Includes: Supplemental data
Journal Articles

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Ariela Noy, MD PhD, Sven de Vos, MD PhD, Catherine Thieblemont, MD PhD, Peter Martin, MD, Christopher Flowers, MDMS, Franck Morschhauser, Graham P. Collins, MD PhD, Shuo Ma, Morton Coleman, MD, Shachar Peles, MD, Stephen Smith, MD, Alina Smith, Brian Munneke, PhD, Isaiah Dimery, MD, Darrin Beaupre, MD PhD, Robert W Chen, MD
Journal: Blood
Blood (2016) 128 (22): 1213.
https://doi.org/10.1182/blood.V128.22.1213.1213
Published: 2016
Journal Articles

Tolerability of PTK787/ZK 222584 in a Phase II Study of Post-Transplant Maintenance Therapy in Patients with Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant.

James C. Mosley, III, MD, Shachar Peles, M.D., Alisa Ruddell, B.A., Feng Gao, M.D., Ph.D., Camille Abboud, M.D., Amanda Cashen, M.D., Geoffrey Uy, M.D., Peter Westervelt, M.D., Ph.D., John F. DiPersio, M. D., Ph.D., Ravi Vij, M.D.
Journal: Blood
Blood (2007) 110 (11): 5109.
https://doi.org/10.1182/blood.V110.11.5109.5109
Published: 2007
Journal Articles

Once Weekly Bortezomib (Velcade) Preserves Bone Health by a Direct Effect on Osteoclast Function Independent of Its Effect on the Malignant Plasma Cells.

Shachar Peles, MD, Nicholas M. Fisher, Feng Gao, MD, PhD, Steven M. Devine, Michael H. Tomasson, MD, John F. DiPersio, MD, PhD, Ravi Vij, MD.
Journal: Blood
Blood (2005) 106 (11): 3458.
https://doi.org/10.1182/blood.V106.11.3458.3458
Published: 2005
Journal Articles

Bortezomib (Velcade) When Given Pretransplant and Once Weekly as Consolidation Therapy Following High Dose Chemotherapy (HDCT) Leads to High Rates of Reactivation of Varicella Zoster Virus (VZV).

Shachar Peles, MD, Nicholas M. Fisher, Steven M. Devine, MD, Michael H. Tomasson, MD, John F. DiPersio, MD, PhD, Ravi Vij, MD
Journal: Blood
Blood (2005) 106 (11): 3237.
https://doi.org/10.1182/blood.V106.11.3237.3237
Published: 2005